恆指升幅擴至近600點 內地疫情嚴峻疫苗股跑贏 康希諾曾續漲15%
港匯再度觸及弱方兌換保證,金管局相隔近兩周於上周末朝早在紐約時段承接30.54億港元沽盤,令明天(8日)本港銀行體系結餘將跌至969.77億港元。恆指繼上周累漲近1,300點或8.7%後,今早在權重新經濟股回吐主導,低開129點或0.8%報16,031,最低見15,980獲承接,在權重金融指數升幅曾擴至4.3%,以及地產和科指倒升2.5%及4.6%推動,掉頭倒升595點或3.7%報16,756總成交額740億元。
內地疫情持續惡化,尤其是廣州新增本土確診病例急增。國家衛健委重申「動態清零」總方針不動搖。內地新冠藥物板塊升1.6%(跑贏滬深股指僅反覆微升)。
本港疫苗股今天仍以康希諾-B(06185.HK)表現最好,股價曾漲15%高見129元,現報124.4元,續升11%;康希諾A(688185.SH)升近8%曾高見271.25元人民幣。
開拓藥物(09939.HK)、藍籌藥明生物(02269.HK)、三葉草生物(02197.HK)及騰盛博藥(02137.HK)續升逾5%-7%,曾分別高見14.06元、46.15元、2.43元及7.56元。然而,復星醫藥(02196.HK)高開報25.4元無以為繼,掉頭低見22.95元, 現報23.35元,逆跌近4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.